Literature DB >> 6135648

Clostridium difficile and inflammatory bowel disease.

C Greenfield, J R Aguilar Ramirez, R E Pounder, T Williams, M Danvers, S R Marper, P Noone.   

Abstract

Stools from 109 patients with inflammatory bowel disease (13.4%) contained Clostridium difficile or its toxin, an incidence similar to the stools of 99 control patients with diarrhoea (11.9%), but significantly higher than the stools of 77 control patients with a normal bowel habit (1.4%). Sixty-six per cent of the diarrhoea controls, but only 11% of the inflammatory bowel disease patients, reported recent antibiotic use: however, 67% of inflammatory bowel disease patients were taking sulphasalazine. The presence of Cl difficile in the stool was not related to the clinical assessment of inflammatory bowel disease relapse, but it was related to hospital admission. During the one year study, 31 of the 109 patients (28%) with inflammatory bowel disease had one or more stool samples that were positive for Cl difficile.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6135648      PMCID: PMC1420228          DOI: 10.1136/gut.24.8.713

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  19 in total

1.  Cytotoxicity assay in antibiotic-associated colitis.

Authors:  T W Chang; M Lauermann; J G Bartlett
Journal:  J Infect Dis       Date:  1979-11       Impact factor: 5.226

2.  Faecal flora of patients with ulcerative colitis during treatment with salicylazosulphapyridine.

Authors:  E M Cooke
Journal:  Gut       Date:  1969-07       Impact factor: 23.059

3.  Effects of sulphasalazine (Salazopyrin) on faecal flora in patients with inflammatory bowel disease.

Authors:  B West; R Lendrum; M J Hill; G Walker
Journal:  Gut       Date:  1974-12       Impact factor: 23.059

4.  Spontaneous pseudomembranous colitis.

Authors:  J M Howard; S N Sullivan; M Troster
Journal:  Br Med J       Date:  1980-08-02

5.  Prevention of necrotising enteritis in Papua New Guinea by active immunisation.

Authors:  G Lawrence; F Shann; D S Freestone; P D Walker
Journal:  Lancet       Date:  1979-02-03       Impact factor: 79.321

Review 6.  Antibiotic-associated pseudomembranous colitis.

Authors:  J G Bartlett
Journal:  Rev Infect Dis       Date:  1979 May-Jun

7.  Clostridium difficile associated diarrhoea: a role in inflammatory bowel disease?

Authors:  R P Bolton; R J Sherriff; A E Read
Journal:  Lancet       Date:  1980-02-23       Impact factor: 79.321

8.  Pseudomembranous colitis: Presence of clostridial toxin.

Authors:  H E Larson; A B Price
Journal:  Lancet       Date:  1977 Dec 24-31       Impact factor: 79.321

9.  Clostridium difficile and the aetiology of pseudomembranous colitis.

Authors:  H E Larson; A B Price; P Honour; S P Borriello
Journal:  Lancet       Date:  1978-05-20       Impact factor: 79.321

10.  Therapeutic implications of Clostridium difficile toxin during relapse of chronic inflammatory bowel disease.

Authors:  J T LaMont; Y M Trnka
Journal:  Lancet       Date:  1980-02-23       Impact factor: 79.321

View more
  16 in total

Review 1.  New pathophysiological insights and modern treatment of IBD.

Authors:  Matthias A Engel; Markus F Neurath
Journal:  J Gastroenterol       Date:  2010-03-09       Impact factor: 7.527

Review 2.  Clostridium difficile: its disease and toxins.

Authors:  D M Lyerly; H C Krivan; T D Wilkins
Journal:  Clin Microbiol Rev       Date:  1988-01       Impact factor: 26.132

Review 3.  Laboratory assessment of inflammatory bowel disease.

Authors:  I T Beck
Journal:  Dig Dis Sci       Date:  1987-12       Impact factor: 3.199

Review 4.  Clostridium difficile infection: clinical spectrum and approach to management.

Authors:  Chetana Vaishnavi
Journal:  Indian J Gastroenterol       Date:  2011-12-20

5.  Clostridium difficile and its cytotoxin in infants admitted to hospital with infectious gastroenteritis.

Authors:  M E Ellis; B K Mandal; E M Dunbar; K R Bundell
Journal:  Br Med J (Clin Res Ed)       Date:  1984-02-18

6.  Prospective study of Clostridium difficile colonization and paracresol detection in the stools of babies on a special care unit.

Authors:  T J Phua; T R Rogers; A P Pallett
Journal:  J Hyg (Lond)       Date:  1984-08

7.  Serogrouping of Clostridium difficile strains by slide agglutination.

Authors:  M Delmee; M Homel; G Wauters
Journal:  J Clin Microbiol       Date:  1985-03       Impact factor: 5.948

8.  Clostridium difficile, sulphasalazine, and ulcerative colitis.

Authors:  D A Burke; A T Axon
Journal:  Postgrad Med J       Date:  1987-11       Impact factor: 2.401

9.  Risk Factors for Clostridium difficile Isolation in Inflammatory Bowel Disease: A Prospective Study.

Authors:  Dejan Micic; Andres Yarur; Alex Gonsalves; Vijaya L Rao; Susan Broadaway; Russell Cohen; Sushila Dalal; John N Gaetano; Laura R Glick; Ayal Hirsch; Joel Pekow; Atsushi Sakuraba; Seth T Walk; David T Rubin
Journal:  Dig Dis Sci       Date:  2018-02-08       Impact factor: 3.199

10.  Prolonged ileus as a sole manifestation of pseudomembranous enterocolitis.

Authors:  Eran Elinav; David Planer; Moshe E Gatt
Journal:  Int J Colorectal Dis       Date:  2003-11-15       Impact factor: 2.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.